The Hemophilia Market size was valued at USD 13.62 billion in 2022 and is expected to reach USD 20.43 billion by 2030 and grow at a CAGR of 5.2 % over the forecast period of 2023-2030.
The Hemophilia market is a rapidly growing sector within the healthcare industry, driven by advancements in treatment options and an increasing prevalence of the condition. Hemophilia is a rare genetic disorder that affects the body’s ability to form blood clots, leading to prolonged bleeding and potential complications.
Get Free PDF Sample Report: https://www.snsinsider.com/sample-request/2705
One of the key factors driving the growth of the Hemophilia market is the development of innovative therapies. Traditional treatment options for hemophilia involved regular infusions of clotting factor concentrates derived from human plasma. However, with advancements in biotechnology, recombinant clotting factors have emerged as a safer and more effective alternative. These recombinant therapies are produced using genetically engineered cells, reducing the risk of transmitting infections and improving patient outcomes.
Moreover, gene therapy has shown promising results in treating hemophilia. Gene therapy involves introducing functional genes into a patient’s body to correct the underlying genetic defect causing hemophilia. Several clinical trials have demonstrated significant improvements in patients’ clotting abilities after receiving gene therapy treatments.
KEY MARKET SEGMENTS
By Therapy Type
- Replacement Therapy
- Clotting Factors
- Plasma-derived factor concentrate
- Recombinant factor concentrate
- Fibrin Sealants
- Physical Therapy
- Immune Tolerance Induction (ITI) Therapy
- Gene Therapy
- Type A
- Type B
- Type C
- Type D
Major Players Listed in the Report are as Follows:
Pfizer, uniQure N.V., CSL, Genentech USA, Inc., Sanofi, Takeda Pharmaceutical Company Limited., Baxalta, Bayer, Novo Nordisk, Alnylam Pharmaceuticals, Biogen and Other Players.
SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.
We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.
Akash Anand – Head of Business Development & Strategy,
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)